by Simran Chahal | Jan 1, 2019 | Business, Health, News
USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex’s Portfolio in the Diagnosis of Rheumatoid Arthritis (RA) On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From...
by Simran Chahal | Feb 25, 2018 | Health
In a study of over 800 rheumatoid arthritis (RA) patients, presented this week at the Canadian Rheumatology (CRA) Association Meeting, it was shown that a positive 14-3-3η blood test amplified the risk of rapid joint damage progression when added to current measures....
by Simran Chahal | Jul 22, 2015 | Health, News
Expanded Use Indications JOINTstat™, a clinically game-changing blood test for Rheumatoid Arthritis (RA), now has expanded use indications in Canada and the EU. This novel test, which measures a protein called 14-3-3η, was first indicated for diagnostic use in RA....
by Simran Chahal | Nov 5, 2014 | Health, News
Vancouver, BC – November 5, 2014. Augurex Life Sciences Corp. announces a burgeoning body of data that further reveals the important role of a protein measured in blood, called 14-3-3eta, in rheumatoid arthritis (RA). Ten studies will be presented at the world’s...
by Simran Chahal | Jun 19, 2014 | Health, News
The National Research Council of Canada (NRC) and Augurex Life Sciences Corp. are proud to announce a collaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine. By combining their research and development expertise, NRC...
by Simran Chahal | May 29, 2014 | Health, News
Vancouver, BC – May 29, 2014. Augurex Life Sciences Corp. announces a ground-breaking body of new data that will publish during the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology taking place June 11-14 in Paris. Investigators will present...
